AngioDynamics vs Axogen
ANGO and AXGN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANGO and AXGN compare
Axogen is the larger company, worth 6.7 times as much as AngioDynamics ($3.5B against $522M).
Axogen grew revenue faster over the last twelve months (24.3% versus 8.2% for AngioDynamics).
AngioDynamics keeps more of each dollar of sales as profit, with a net margin of −10.1% compared with −12.0% at Axogen.
AngioDynamics scores higher on the StockData Score (12 against 11 for Axogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANGO | AXGN |
|---|---|---|
| Size and price | ||
| Market cap | $522M | $3.5B |
| Share price | $12.42 | $58.63 |
| Change, 1 year | 1.1% | 144% |
| Change, 5 years | −56.5% | 501% |
| Beta (5Y) | 0.34 | 1.16 |
| Employees | 632 | 622 |
| StockData Score | ||
| Total score | 12 (better) | 11 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 3 | 3 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.6× (better) | 13.1× |
| P/B | 3.2× (better) | 7.1× |
| P/FCF | 362× | 159× (better) |
| FCF yield | 0.28% | 0.63% (better) |
| Fair value | $13.24 | $22.84 |
| Margin of safety | 6.2% (better) | −157% |
| Growth | ||
| Revenue growth (TTM) | 8.2% | 24.3% (better) |
| Revenue growth, 5Y average | 1.9% | 14.9% (better) |
| Profitability | ||
| Gross margin | 55.7% | 74.2% (better) |
| Operating margin | −11.2% | −5.2% (better) |
| Net margin | −10.1% (better) | −12.0% |
| FCF margin | 0.44% | 8.3% (better) |
| Return on equity | −19.2% | −10.3% (better) |
| Return on invested capital | −21.4% | −7.9% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −5.7× |
| Current ratio | 2.40 | 12.02 (better) |
| Altman Z-score | 2.54 | 39.19 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 91.0% | 90.4% |
| Held by insiders | 5.8% | 7.6% |
| Insider net buying, 12 months | −$655K (better) | −$17.1M |
| Short interest, % of float | 5.1% | 12.7% |
Go deeper
- ANGO stock overview
- ANGO income statement
- ANGO valuation and score
- AXGN stock overview
- AXGN income statement
- AXGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.